Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinomaMarlon C. Rebelatto, Jill Walker|Diagnostic Pathology|2016Cited by 179
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Ying Cheng et al.|Journal of Thoracic Oncology|2022Cited by 72
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Ricard Mesı́a, Weimin Li et al.|Clinical Cancer Research|2023Cited by 30